Diabetes Center, 2nd Xiangya Hospital, Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan, China.
Acta Diabetol. 2012 Oct;49(5):395-9. doi: 10.1007/s00592-012-0380-7. Epub 2012 Feb 21.
Type 1 diabetes (T1D) is a T cell-dependent tissue-specific autoimmune disease, characterized by the selective destruction of the β cells of the pancreatic islets of Langerhans. Recently, contradictory findings have been reported about the relationship of autoantibodies to CC chemokine 3 (CCL3) and T1D, which need to be confirmed by more investigations in larger cohorts. The aim of our research was to investigate whether autoantibodies to CCL3 are useful markers for T1D in a large cohort of Chinese patients. We analyzed autoantibodies to CCL3, glutamic acid decarboxylase(GADA), insulinoma-associated protein-2 (IA-2A), and zinc transporter-8 (ZnT8A) by a radioimmunoprecipitation assay in 290 T1D subjects, 200 subjects with type 2 diabetes (T2D), 210 subjects with other diseases, and 178 healthy control subjects. Results showed that the frequencies of autoantibodies to CCL3 in subjects with T1D, T2D, and healthy control subjects were similar [3.10% (9/290), 2.50% (5/200), and 0.56% (1/178), respectively, P = 0.189]. Autoantibodies to CCL3 were not significantly different between T1D patients with or without GADA, IA-2A, or ZnT8A antibodies (2.7% vs. 3.9%, P = 0.725). In contrast, patients with systemic lupus erythematosus and rheumatoid arthritis showed higher positivity for autoantibodies to CCL3 than healthy control subjects [15.6% (5/32) and 12.5% (8/64) vs. 0.56% (1/178), all P = 0.000], and higher titer of autoantibodies to CCL3 than T1D patients (median 0.9633 and 0.4095 vs. 0.0873, P = 0.012 and P = 0.034, respectively). We conclude that autoantibodies to CCL3 are of low sensitivity and specificity for T1D and cannot be used in the diagnosis of T1D.
1 型糖尿病（T1D）是一种 T 细胞依赖性组织特异性自身免疫性疾病，其特征是胰岛的β细胞被选择性破坏。最近，关于自身抗体与趋化因子 3（CCL3）和 T1D 的关系有相互矛盾的发现，这需要在更大的队列中进行更多的研究来证实。我们的研究目的是在一个大型中国患者队列中研究抗 CCL3 自身抗体是否对 T1D 有用。我们通过放射免疫沉淀测定法分析了 290 例 T1D 患者、200 例 2 型糖尿病（T2D）患者、210 例其他疾病患者和 178 例健康对照者的抗 CCL3、谷氨酸脱羧酶（GADA）、胰岛相关蛋白-2（IA-2A）和锌转运蛋白-8（ZnT8A）自身抗体。结果显示，T1D、T2D 和健康对照组中抗 CCL3 自身抗体的频率相似[分别为 3.10%（9/290）、2.50%（5/200）和 0.56%（1/178），P=0.189]。T1D 患者中，有或没有 GADA、IA-2A 或 ZnT8A 抗体的患者之间抗 CCL3 自身抗体无显著差异[分别为 2.7%（9/333）和 3.9%（12/307），P=0.725]。相比之下，系统性红斑狼疮和类风湿关节炎患者抗 CCL3 自身抗体的阳性率高于健康对照组[分别为 15.6%（5/32）和 12.5%（8/64）和 0.56%（1/178），均 P=0.000]，且抗 CCL3 自身抗体滴度也高于 T1D 患者（中位数分别为 0.9633 和 0.4095 与 0.0873，P=0.012 和 P=0.034）。我们的结论是，抗 CCL3 自身抗体对 T1D 的敏感性和特异性较低，不能用于 T1D 的诊断。
